-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie announced that the SKYRIZI® subcutaneous administration induction treatment plan has been approved by the US Food and Drug Administration to treat adult patients with moderately to severely active Crohn's disease.

Zhitongcaijing·10/27/2026 04:09:03
Listen to the news
AbbVie announced that the SKYRIZI® subcutaneous administration induction treatment plan has been approved by the US Food and Drug Administration to treat adult patients with moderately to severely active Crohn's disease.